Analysis of the effects of donor and recipient hepatitis C infection on kidney transplant outcomes in the United States

Table 4 Patient survival and death-censored graft survival at 3 years in the pre-direct-acting antivirals era and the post-direct-acting antivirals era

Cohorts in comparison (%)			D-R+	D+R+	D-R-	D+R-	Absolute risk difference
Crude	Patient survival	Pre	86.7 (85.8, 87.7)	84.8 (83.4, 86.3)	89.6 (89.5, 89.8)	73.1 (69.4, 76.9)	-
		Post	88.1 (85.7, 90.5)	89.8 (87.7, 92)	91 (90.6, 91.3)	86.1 (77.6, 95.6)	-
	Death-censored graft survival	Pre	84.2 (83.1, 85.3)	82 (80.4, 83.6)	88.8 (88.6, 89)	80.1 (76.6, 83.7)	-
		Post	92.4 (90.6, 94.2)	94.2 (92.5, 96)	92.5 (92.2, 92.8)	92.6 (87.3, 98.3)	-
D+ vs D- in R+	Patient survival	Pre	86.3 (84.4, 88.2)	84.8 (82.8, 86.8)	-	-	3.3 (1.8, 4.7)
		Post	90.2 (85.5, 95)	88.7 (84, 93.7)	-	-	2.7 (-2.9, 8.1)
	Death-censored graft survival	Pre	83.6 (81.5, 85.8)	81.6 (79.4, 83.9)	-	-	3.1 (1.2, 5)
		Post	90.1 (85.5, 94.9)	92 (87.9, 96.3)	-	-	0.4 (-5, 6.1)
D+ vs D- in R-	Patient survival	Pre	-	-	85.3 (82.3, 88.4)	73.5 (69.8, 77.4)	8 (5.2, 10.9)
		Post	-	-	89.1 (83.6, 94.9)	88.6 (81.6, 96.2)	-0.3 (-5.9, 6.1)
	Death-censored graft survival	Pre	-	-	86.9 (83.9, 89.9)	80.4 (76.8, 84.1)	7.4 (4.3, 10.5)
		Post	-	-	92.2 (87.8, 96.8)	93.8 (88.5, 99.4)	-2.3 (-7.4, 2.1)
R+ vs R- in D+	Patient survival	Pre	-	80.9 (77.3, 84.6)	-	76.7 (72.8, 80.7)	0.1 (-2.9, 3.1)
		Post	-	88.4 (84.3, 92.8)	-	85.1 (75.4, 96)	1.1 (-6.1, 7)
	Death-censored graft survival	Pre	-	79.4 (75.5, 83.5)	-	80.6 (76.9, 84.6)	1.2 (-2.5, 4.9)
		Post	-	93 (89.6, 96.5)	-	92.3 (86.2, 98.8)	0.7 (-5, 5.4)
R+ vs R- in D-	Patient survival	Pre	86.7 (85.8, 87.7)	-	88.7 (87.8, 89.6)	-	2.6 (1.9, 3.2)
		Post	88.1 (85.7, 90.5)	-	89.5 (87.3, 91.8)	-	-0.5 (-3.3, 2.2)
	Death-censored graft survival	Pre	84.2 (83.1, 85.3)	-	86.5 (85.5, 87.5)	-	3.5 (2.6, 4.4)
		Post	92.4 (90.6, 94.2)	-	92.1 (90.2, 94.1)	-	-0.2 (-2.4, 2)
D+R+ vs D-R-	Patient survival	Pre	-	85 (83.4, 86.5)	89 (87.7, 90.4)	-	5.3 (4.3, 6.4)
		Post	-	88.4 (85.5, 91.4)	91.8 (89.2, 94.4)	-	3.3 (0, 6.7)
	Death-censored graft survival	Pre	-	82.7 (81, 84.4)	87.8 (86.4, 89.2)	-	7.1 (5.7, 8.5)
		Post	-	93.3 (90.9, 95.8)	93.3 (90.9, 95.8)	-	1.7 (-1.4, 4.5)
D+R- vs D-R+	Patient survival	Pre	85.4 (82.1, 88.8)	-	-	75.6 (71.6, 79.7)	5.4 (2.6, 8.6)
		Post	88.7 (81.8, 96.3)	-	-	91.5 (85, 98.6)	3.2 (-5.9, 11.6)
	Death-censored graft survival	Pre	84.5 (81.1, 88.1)	-	-	81.1 (77.3, 85.1)	4.8 (1.4, 8.2)
		Post	94.4 (89.3, 99.7)	-	-	93.3 (87.4, 99.5)	2.5 (-3.6, 10)

D(-/+) R(-/+), hepatitis C virus (-) or (+) donors into hepatitis C virus (-) or (+) recipients. Pre: Pre-direct-acting antivirals era; Post: Post-direct-acting antivirals era.